Severe drug-associated colitis with Crohn’s features in setting of ixekizumab therapy for chronic plaque psoriasis

Severe drug-associated colitis with Crohn’s features in setting of ixekizumab therapy for chronic plaque psoriasis

Abstract Background Ixekizumab is monoclonal antibody targeted against interleukin-17 (IL-17) and has been approved for use in chronic plaque psoriasis. Despite its efficacy in treating psoriasis, concerns have been raised regarding Ixekizumab’s potential to induce and exacerbate inflammatory bowel...

Full description

Bibliographic Details
Main Authors: Xin Mu, John Fardy, Stephanie Reid, Julia Trahey
Format: Article
Language:English
Published: BMC 2021-10-01
Series:BMC Gastroenterology
Subjects:
Ixekizumab
Inflammatory bowel disease
Drug-associated colitis
Psoriasis
Case report
Online Access:https://doi.org/10.1186/s12876-021-01936-w

Internet

https://doi.org/10.1186/s12876-021-01936-w

Similar Items